Title:
経口投与用固形組成物
Document Type and Number:
Japanese Patent JP7239495
Kind Code:
B2
Abstract:
The present invention relates to solid compositions for oral administration comprising (i) a GLP-1 derivative and the SGLT2 inhibitor dapagliflozin or (ii) a GLP-1 derivative and a salt of NAC in combination with an SGLT2 inhibitor.
Inventors:
Vedge, Andreas
Schuell, Sae Yamamoto
Bjell Legard, Simon
Schuell, Sae Yamamoto
Bjell Legard, Simon
Application Number:
JP2019567972A
Publication Date:
March 14, 2023
Filing Date:
June 11, 2018
Export Citation:
Assignee:
Novo Nordisk A/S
International Classes:
A61K38/26; A61K9/14; A61K9/20; A61K9/48; A61K47/12; A61K47/26; A61P3/04; A61P3/10
Domestic Patent References:
| JP2014503526A |
Foreign References:
| WO2017004623A1 |
Other References:
Tissue Barriers (2016) vol.4, no.2, e1176822, p.1-13
Lancet Diabetes Endocrinol. (2016) vol.4, issue 12, p.1004-1016
Diabetes Obes. Metab. (Jan 2017) vol.19, issue 1, p.49-60
Lancet Diabetes Endocrinol. (2016) vol.4, issue 12, p.1004-1016
Diabetes Obes. Metab. (Jan 2017) vol.19, issue 1, p.49-60
Attorney, Agent or Firm:
Murayama Yasuhiko
Shinya Mihiro
Tatsuhiko Abe
Shinya Mihiro
Tatsuhiko Abe